However, questions remain about whether taking them together is advisable and how they affect one another
During an open public hearing before the vote, the panel heard from multiple speakers, including public health advocates, physicians, and peptide companies, who expressed widely differing views on whether BPC-157 should be included on the 503A bulk drug list
This guide covers everything, from the science of what happens inside your body when GLP-1 signaling stops, to week-by-week tapering protocols, to the exact lifestyle adjustments that separate people who maintain their results from those who do not
The trial resulted in an average weight loss of 16.0 lbs/7.3 kg (7.9%) at the highest dose as a key secondary endpoint
These findings are meaningful though most studies are small, follow-up periods are limited, and there is not yet sufficient evidence to recommend GLP-1 medications as a treatment for eating disorder symptoms ( Bartel et al., Int J Eating Disorders, 2024 )
& Zheng, N